All In Biotech

Drug Trial Radar · NCT06001619

Prostate Medication, Metabolism and Gut Microbiota

Last checked: Nov 20, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 1, 2022

Primary completion

Oct 31, 2024

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Turku University HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PROMED is a prospective, single center translational multiple cohort study to investigate the association of prostate medication and gut microbiota. The main aim is to investigate how prostate hormonal therapy (5-ARI, ADT) affects gut microbiota composition. Aalso study metabolic characteristics in the gut and systemic circulation in men with different medications will be studied. In addition, the effect of gut microbiota on patient's response to medications will be investigated. The medicines used in the study to treat benign prostate hyperplasia are dutasteride and finasteride and a combination of dutasteride and tamsulosin. LHRH antagonist degarelix is used as a medication to treat patients with cancer. The dosages of 5-ARI medication: dutasteride 0,5mg x1 or finasteride 5mg x1 or combination of dutasteride and tamsulosin 0,5/0,4mg x1. The starting dose of LHRH antagonist degarelix is 120mgx2 and the maintenance dose is 80mgx1. The medication for PCa is planned according to the protocol but so that each subject receives degarelix at the beginning of treatment and one month after initiation. Thereafter, the medication is continued according to the clinician's assessment. The study is carried out in Turku University Hospital and University of Turku.

Conditions

  • Prostatic Hyperplasia
  • Prostate Cancer

Interventions

  • Prostate hyperplasia medicationDrug

    The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.

  • LhRH-antagonistDrug

    The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Gut microbiota signature before 5-ARI therapyTime frame: before starting prostate 5-ARI medication
  2. Gut microbiota signature after 5-ARI therapyTime frame: 2 months after starting prostate 5-ARI medication
  3. Gut microbiota signature before ADT (LHRH antagonists).Time frame: before starting prostate degarelix
  4. Gut microbiota signature after ADT (LHRH antagonists).Time frame: 2 months after starting prostate degarelix

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Turku University Hospital

    Turku, Finland · Recruiting

  • University of Turku

    Turku, Finland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.